Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

NCT02657447 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study is no longer relevant

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Betalutin with lilotomab dose 1
DRUG: Betalutin with lilotomab dose 2

Sponsor

Nordic Nanovector